On June 1, 2023 Shasqi, Inc. ("Shasqi"), a clinical-stage biotech company, whose mission is to revolutionize cancer treatment with click chemistry, reported that it has entered into a research collaboration with Johnson & Johnson Enterprise Innovation Inc (Press release, Shasqi, JUN 1, 2023, View Source [SID1234632373]). Through the collaboration, Shasqi will apply its novel tumor-targeted Click Activated Protodrugs Against Cancer (CAPAC) platform to the development of new cancer therapies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Shasqi’s CAPAC platform relies on chemistry, not biology, for activation of drugs at the tumor. The platform is made up of two separate components: a tumor-targeting agent and a cancer therapeutic. These come together at the site of the tumor, and the cancer therapeutic is activated via click chemistry, a Nobel Prize winning technology. Using this platform, Shasqi is targeting high doses of cancer drugs directly to the site of the tumor, while minimizing toxicity to healthy cells. Shasqi is the first company to use click chemistry in humans.
"This is a compelling opportunity to expand our platform," said José M. Mejía Oneto, MD, PhD, founder and chief executive officer of Shasqi. "We are excited to collaborate and apply click chemistry for potential new therapies in areas of significant unmet medical need."
The use of click chemistry to activate cancer drugs at the tumor has been clinically validated. In a phase 1 study, click chemistry was used to activate a dose of doxorubicin that is 12-times a conventional dose, with a favorable toxicity profile. Tumor localization of click chemistry was achieved through an intratumorally injected biopolymer. A phase 2a study is currently enrolling patients with soft tissue sarcoma and head and neck cancer.[1]
The collaboration will focus on Shasqi’s intratumorally injected biopolymer (SQL70) and a co-development committee has been formed with the aim of identifying the next clinical candidate.
"This marks the start of Shasqi’s ambition to advance our platform and collaboratively develop the next generation of tumor-targeted therapies, expanding on the foundation built by antibody drug conjugates," said Mukul Agarwal, chief business officer at Shasqi. "The reliance on chemistry, not biology for drug activation, allows for the use of small molecules, peptides, and antibody fragments to target tumor antigens, creating unprecedented flexibility."